Onkologie. 2008:2(1):49-52
AN UPDATE IN BREAST CANCER TREATMENT
- Masarykův onkologický ústav, Brno
Therapy of breast cancer is multiplex. Systemic therapy includes chemotherapy, hormonal therapy, and recently also biological therapy. We present the latest data from pooled analysis of NSABP B-31 and NCCTG-N9831 clinical trials, then data concerning lapatinib, results of phase III clinical trial comparing lapatinib with combination of lapatinib/kapecitabin in patients resistant to trastuzumab. We briefly mention treatment options of triple negative breast cancer-especially an effort of a targeted therapy of these chemosensitive but aggressive tumors. Aromatase inhibitors improve treatment results of early breast cancer in all females groups. Upfront of therapy with anastzrozol or letrozol reaches the same effect of recurrence reduction during first 2–3 years. Neither PgR. HER 2 nor age are influencing the response to adjuvant hormonal therapy in postmenopausal patients.
Keywords: breast cancer, biological therapy, triple negative breast cancer, hormonal therapy
Published: April 1, 2008 Show citation
References
- Perez EA, Romond EH, Suman VJ, Davidson NE, Geyer CE et al. NCCTG/NSABP; Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotehrapy with/without trastuzumab in patiens with HER2-positive breast cancer, 43 rd Annual ASCO Meeting, Chicago, USA Jun 2007. Abstract 512.
Go to original source... - Smith I, Procter M, Gerber R et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 2007; 369: 29-36. Go to original source...
Go to PubMed... - Ozols R, Herbst R, Colson Y. et al. Clinical cancer Advances 2006. Major Research Advances in cancer treatment, Prevention, and Screening - A report From the ASCO. J Clin Oncol 2007; 25: 146-161. Go to original source... Go to PubMed...
- Slamon R, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamid followed by docetacel (ACT) with doxorucibin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER 2 positive early breast cancer patiens: BCIRG 006 study. 28 th San Antonio Breast Cancer Symposium. San Antonio USA, Dec 2005, abstract 1.
- Zeyer CE, Foerster JK, Cameron D et al. Lapatinib in trastuzumab resistant breast cancer, 42nd Annual ASCO Meeting June 2006, Atlanta USA.
- Cleator S, Keller W, Coombes RCh. Triple-negative breast cancer: therapeutic options. The Lancet 2007; 8: 235-244. Go to original source... Go to PubMed...
- Haffty BG, Yang Q, Weiss M et al. Locoregional Relapse and Distanc Metastasi in Conservatively manager Triple Negative Early-Stage Breast Cancer. J Clin Oncol 2006; 24: 5652-5657. Go to original source... Go to PubMed...
- Mandelů J, Monypenny IJ, Skene AI et al. Predictors of early recurrence in postmenopausal women with operable breast cancer, Breast Cancer Res Treat. 2006; 100 (suppl. 1), abstrakt 2091.
- Coombes RC, Kilburn LS, Paridaens CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (IES): a randomized trial, The Lancet 2007; 369: 559-570. Go to original source... Go to PubMed...
- Cuzick J, Sasieni P, Howell A et al. Optimal use of aromatase inhibitors for adjutant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen? 43rd Annual ASCO meeting, Chicago, USA; June 2007, Abstract 541. Go to original source...
- Coates A, Keshaviah A, Thurlimann B et al. Five Years of Letrozole Compared With Tamoxifen As initial Adjutant Therapy for Postmenopausal Women With Endocrine-Resůponsive Early Breast Cancer: Update of Study BIG 1-98, J Clin Oncol 2007; 25: 486-492. Go to original source... Go to PubMed...